12 Participants Needed

A Proof-of-Concept Study Evaluating LINFU™

SL
Overseen ByStephanie Lazarus
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Adenocyte, LLC
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. Please consult with the study team for guidance.

What is the purpose of this trial?

This trial uses the LINFU™ Technique, which employs ultrasound and a special dye to collect pancreatic fluid. It targets people at high risk for pancreatic cancer. The method involves stimulating the pancreas to release fluid, which is then collected and analyzed.

Research Team

SC

Scott Corbett, MD, FASGE

Principal Investigator

Suncoast Endoscopy of Sarasota (a division of Florida Digestive Health Specialists)

Eligibility Criteria

Inclusion Criteria

You have a high chance of getting pancreatic cancer.
Institutional Review Board (IRB)-approved consent must be signed by patients to participate in this study.
You will need to undergo an EUS or MRI scan as part of your screening.

Exclusion Criteria

Pregnant females will be excluded.
Patient under the age of 18 and over the age 90
The study investigators have determined that you cannot undergo EUS (endoscopic ultrasound) due to certain reasons.
See 7 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

LINFU™ Procedure

Participants undergo the LINFU™ Technique, which involves ultrasound excitation of the pancreas, administration of Lumason and secretin, and collection of pancreatic fluid

1 day
1 visit (in-person)

Follow-up

Participants are monitored for symptoms of pancreatitis and undergo blood tests to measure lipase levels

4 weeks
2 follow-up calls, 1 visit if symptoms develop

Treatment Details

Interventions

  • LINFU™
Participant Groups
1Treatment groups
Experimental Treatment
Group I: The LINFU™ testExperimental Treatment1 Intervention
LINFU™ to increase sensitivity of pancreatic juice cytology LINFU™ consists of analysis of pancreatic fluid collected with the help of low intensity non-focused ultrasound excitation of the pancreas. Lumason, will be used to create bubbles and possibly increase the number of pancreatic cell we collect for the study. Secretin is also used to increase the number of pancreatic cell excretion to maximize the number of cells collected.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Adenocyte, LLC

Lead Sponsor

Trials
6
Recruited
3,500+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security